Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07206511 | Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study(THAI-CONVERT) | not yet recruiting | — | 278 | Shanghai Zhongshan HospitalOTHER | 0 | Oct 3, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 1 |
| Oct 3, 2025 |
| clinicaltrials |
| NCT02968069 | A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions | not yet recruiting | N/A | 300 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Oct 2, 2025 | clinicaltrials |
| NCT07203898 | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 1 | 36 | Beijing Immupeutics Medicine Technology LimitedINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT07201064 | A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 12 | Guangdong ProCapZoom Biosciences Co., Ltd.INDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06861855 | Prognosis of METTL-14 in Endometrial Carcinoma | not yet recruiting | — | 50 | Assiut UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198672 | Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag | not yet recruiting | N/A | 45 | Zhenzhen LiuOTHER_GOV | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07200154 | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07192848 | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | not yet recruiting | Phase 2 | 47 | Song PengOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07187674 | The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel | not yet recruiting | N/A | 20 | Harbin Medical UniversityOTHER | 0 | Sep 23, 2025 | clinicaltrials |
| NCT07187284 | EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 62 | Zhongda HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07183566 | CT Volume Measurement of Hepatocellular Carcinoma | not yet recruiting | — | 66 | Assiut UniversityOTHER | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07179939 | Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study | not yet recruiting | Phase 2 | 288 | Fudan UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07180459 | The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study | not yet recruiting | — | 118 | Xuhua DuanOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07160361 | Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB | not yet recruiting | Phase 4 | 56 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07161115 | Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer(REFIRT) | not yet recruiting | Phase 2 | 60 | Longhao LiOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | not yet recruiting | — | 300 | Tianjin First Central HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07173946 | Prospective Observational Study on ES-SCLC | not yet recruiting | — | 96 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07164690 | Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy | not yet recruiting | Phase 2 | 32 | Fudan UniversityOTHER | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07040644 | A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT07156617 | A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data | not yet recruiting | — | 2,000 | Xuhua DuanOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07157306 | Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153965 | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07156019 | Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | not yet recruiting | Phase 3 | 740 | Tempest TherapeuticsINDUSTRY | 0 | Sep 3, 2025 | clinicaltrials |
| NCT07141147 | A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery. | not yet recruiting | N/A | 58 | Sun Yat-sen UniversityOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07151326 | Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy(CAPIO) | not yet recruiting | Phase 2 | 60 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152535 | Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor(PKU-ESCC) | not yet recruiting | — | 255 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 3, 2025 | clinicaltrials |
| NCT07150377 | A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 41 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT07144995 | MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma | not yet recruiting | — | 1,143 | Sun Yat-sen UniversityOTHER | 0 | Aug 28, 2025 | clinicaltrials |
| NCT06989671 | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC | not yet recruiting | Phase 2 | 430 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 27, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137858 | Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study | not yet recruiting | Phase 2 | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07131501 | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07130474 | Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma | not yet recruiting | — | 50 | Sohag UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07128251 | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | not yet recruiting | Phase 2 | 47 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07120750 | Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis(PRTRAS 001) | not yet recruiting | — | 332 | Shenzhen Third People's HospitalOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT07117279 | A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma | not yet recruiting | — | 120 | Tongji HospitalOTHER | 0 | Aug 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2025source: clinicaltrials